Pro-life voters, who propelled President Trump’s 2026 reelection, now demand the firing of FDA Commissioner Dr. Marty Makary for refusing to restrict the abortion pill mifepristone despite safety alarms.
Story Highlights
- FDA approved a second generic mifepristone in early 2026, fueling pro-life outrage over telehealth distribution bypassing state bans.
- Mike Pence labels HHS Secretary Robert F. Kennedy Jr.’s inaction a “complete betrayal,” while Sen. Josh Hawley declares no confidence in FDA leadership.
- Live Action’s investigation reveals 27 Planned Parenthood sites skipping required ultrasounds and Rh tests, highlighting regulatory noncompliance.
- Louisiana AG leads 20+ GOP attorneys general in lawsuits; a judge notes a strong case but declines immediate block, with appeal to 5th Circuit.
- Pro-life groups warn of midterm voter backlash as HHS studies adverse events, expected to report in six months with no suspensions yet.
Historical Approvals and Recent Expansions
The FDA approved mifepristone in 2000 for pregnancies up to seven weeks. Regulators expanded access in 2016 to 10 weeks and in 2021 allowed telehealth and mail-order distribution during COVID. The Supreme Court upheld this in June 2024’s FDA v. Alliance for Hippocratic Medicine. Early 2026 brought a second generic approval, intensifying criticism. Pro-life advocates argue these steps undermine state bans in 13 jurisdictions, prioritizing access over safety protocols. This pattern erodes trust in federal agencies among conservatives valuing life protections.
Pro-Life Activists Escalate Demands
Live Action released an April 2026 video and letter demanding mifepristone suspension and tighter rules. Their probe found Planned Parenthood clinics dispensing pills without ultrasounds or Rh testing at 27 sites, violating FDA’s REMS program. EPPC reported 11% adverse events like sepsis and hemorrhage—22 times clinical trial rates. Mike Pence called for RFK Jr.’s resignation. Sen. Josh Hawley expressed no confidence in Makary. These actions spotlight perceived regulatory failures endangering women.
Lawsuits and Political Pressures Mount
Louisiana AG Elizabeth Murrill filed suit in April 2026 to reinstate safeguards; a judge declined a block but acknowledged a strong case, sending it to the 5th Circuit. Over 20 GOP AGs support this effort. The Trump White House ignored December 2025 firing calls for Makary, opting for HHS review. SBA Pro-Life America and FRC’s Tony Perkins warn of voter alienation ahead of midterms. This tests the administration’s pro-life commitments amid demands for accountability from its base.
Pro-Life Voters Are Losing Patience With the FDAhttps://t.co/HsgBV8MXJW
— PJ Media (@PJMedia_com) May 9, 2026
Broader Implications for Trust and Governance
Pro-life frustration risks GOP midterm losses as supporters feel betrayed by delays favoring “evidence” over moral and safety imperatives. HHS’s ongoing study may prompt REMS changes, but no immediate action persists. Critics like Cato Institute decry FDA politicization harming patient autonomy. This saga underscores shared bipartisan distrust in federal bureaucracies, where elites seem to prioritize self-preservation over protecting life and enforcing traditional values. Conservatives urge swift reforms to restore faith.
Sources:
When the FDA Becomes Political, Patients’ Autonomy Suffers
Pro-life organization calls on HHS, FDA to suspend abortion pill approval, tighten safety rules
US abortion opponents want Trump’s FDA to act on abortion pill restrictions
WH Ignores Demands From Pro-Life Lobby To Fire FDA Commissioner
FDA v. Alliance for Hippocratic Medicine Supreme Court Opinion
